Pfizer now expects earnings per share of $6.25 to $6.45 per share for the year, down from its previous outlook of $6.35 to $6.55 per share
However, Pfizer beat on its top and bottom lines in its first-quarter earnings report, driven by strong sales of its Covid vaccine and oral antiviral treatment.
